Bookmarks
The effectiveness of opicapone treatment compared to entacapone in Parkinson's disease using electronic primary healthcare records and linked secondary care data
Safe People
Organisation name
Pharmatelligence Ltd
Organisation sector
Commercial
Applicant name(s)
Craig Currie - Chief Investigator - Pharmatelligence LimitedEllen Berni - Corresponding Applicant - Pharmatelligence LimitedDavid Heaton - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Francesca Morgante - Collaborator - St George's
University of LondonK Ray Chaudhuri - Collaborator - King's College LondonMatthew O'Connell - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Myriam Alexander - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Rhiannon Thomason - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Stoyan Minchev - Collaborator - Bial Phama UK LtdValentina Di Foggia - Collaborator - Bial Phama UK Ltd
Safe Projects
Project ID
CPRD462
Lay summary
Opicapone is a treatment for Parkinson’s disease patients which is added to other therapies when symptoms are not controlled (known as end of dose on-off phenomena). Although Parkinson’s disease is diagnosed by its motor symptoms, non-motor symptoms such as sleep disturbances are also prevalent and can be more disabling than the motor symptoms.
Technical summary
Parkinson’s disease is associated with disabling motor and non-motor symptoms (including sleep disturbances). Opicapone is a catechol-O-methyltransferase (COMT) inhibitor indicated in Parkinson’s disease as an adjunct to levodopa and dopa-decarboxylase inhibitors in patients with end-of-dose motor fluctuations. This study aims to evaluate the effectiveness of opicapone in Parkinson’s disease in routine practice.
Latest approval date
24/03/2021
Safe Data
Dataset(s) name
HES Accident and Emergency
HES Admitted Patient Care
HES Outpatient
Safe Setting
Access type
Release